Publications

2019

1.       Minata, M^#., Audia, A^#., Lu, S., Xue, J., Kim, S-H., Guo, X., Mohyeldin, A., Shi, J., Gallego-Perez, D., Pavlyukov, M.S., Wang, J., Chen, D., Cheng, P., Ezhilarasan, R., Mukheef, F., Vaillant, B.D., Sulman, E.P., Cheng, S-Y., Lu, X., Lee, L.J., Nakano, I* and Bhat, K.P.* Dynamic alteration of cancer stem cell regulators in glioblastoma. Cell Rep., in press.

2018

2.       D’Angelo, F., Ceccarelli, M., Garofano, L., Zhang, J., Frattini, V., Caruso, F.P., Alfaro, K.D., Bauchet, L., Berzero, G., Cachia, D., Cangiano, M., Capelle, L., de Groot, J., Di Meco, F., Ducray, F., Farah, W., Finocchiaro, G., Goutagny, S., Kamiya-Matsuoka, C., Loiseau, H., Lorgis, V., Marras, C. E., McCutcheon, I., Mokhtari, K., Nam, D-H., Ronchi, S., Saletti, V.,  Seizeur, R., Slopis, J., Vandenbos, F., Varlet, P., Vidaud, D., Watts, C., Tabar, V., Reuss, D.E., Kim, S-K., Salvador, H., Bhat, K.P., Eoli, M., Sanson, M., Lasorella, A., and Iavarone, A. The Molecular Landscape of Glioma in Patients with Neurofibromatosis-1. Nat. Med., doi: 10.1038/s41591-018-0263-8, 2018.

3.       Conroy, S., Kruyt, F.A.E., Wagemakers, M., Bhat, K.P.L*., den Dunnen, W.F.A*. IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. Oncotarget. 9(21):15721-15731, 2018.

2017

4.       Boyd, N.H., Walker, K., Fried, J., Hackney, J.R., McDonald, P.C., Benavides, G.A., Spina, R., Audia, A., Scott, S.E., Libby, C.J., Tran, A.N., Bevensee, M.O., Griguer, C., Nozell, S., Gillespie, G.Y., Nabors, B., Bhat, K.P., Bar, E.E., Darley-Usmar, V., Xu, B., Gordon, E., Cooper, S.J., Dedhar, S., and Hjelmeland AB. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight., 2(24): 92928, 2017.

5.       Moreno, M., Pedrosa, L., Paré, L., Pineda, E., Bejarano, L., Martínez, J., Balasubramaniyan, V., Ezhilarasan, R., Kallarackal, N., Kim, S.H., Wang, J., Audia, A., Conroy, S., Marin, M., Ribalta, T., Pujol, T., Herreros, A., Tortosa, A., Mira, H., Alonso, M.M., Gómez-Manzano, C., Graus, F., Sulman, E.P., Piao, X., Nakano, I., Prat, A., Bhat, K.P., and de la Iglesia, N. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Cell Rep., 21(8): 2183-2197 2017.

6.       Boonyawan, K., Hess, K.R., Yang, J., Long, L., Wang, Q., Ezhilarasan, R., Auia, A., Alfaro-Munoz, K.D., de Groot, J.F., Bhat, K.P., and Sulman, E.P. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget, 8(52):90488-90495, 2017.

7.       Li, M., Xiao, A., Floydm, D., Olmez, I., Lee, J., Godlewski, J., Bronisz, A., Bhat, K.P.L., Sulman, E.P., Nakano, I., and Purow, B. CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget, 8(33):55319-55331, 2017.

2016

8.       Cheng, P., Wang, J., Waghmare, I., Sartini, S., Coviello, V., Zhang, Z., Kim, S.H., Mohyeldin, A., Pavlyukov, M.S., Minata, M., Valentim, C.L., Chhipa, R.R., Bhat, K.P., Dasgupta, B., La Motta, C., Kango-Singh, M., Nakano, I. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. Cancer Res., 76(24):7219-7230, 2016.

9.       Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L.M., Maiti, S.N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., Liebelt, B.D., Yaghi, N.K., Ezhilarasan, R., Huang, N., Weinberg, J.S., Prabhu, S.S., Rao, G., Sawaya, R., Langford, L., Bruner, J.M., Fuller, G.N., Bar-Or, A., Li, W., Colen, R.R., Curran, M.A., Bhat, K.P., Antel, J.P., Cooper L.J., Sulman, E.P., Heimberger, A.B. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 1(2). pii: e85841, 2016.

10.   Kim, S-H., Ezhilarasan, R., Phillips, E., Gallego-Perez, D., Sparks, A., Taylor, D., Ladner, K., Furuta, T., Sabit, H., Chhipa, R., Cho, J-H., Mohyeldin, A., Beck, S., Kurozumi, K., Kuroiwa, T., Iwata, R., Asai, A., Kim, J., Sulman, E.P., Cheng, S-Y., Lee, L.J., Nakada, M., Guttridge, D., DasGupta, B., Goidts, V., Bhat, K.P., and Nakano, I. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in a NF-κB-dependent Manner. Cancer Cell*, 29 (2): 201–213, 2016.

*Highlights from the Literature, Neuro Oncol., 18(8):1040-2, 2016.

2015

11.   Sathyan, P., Zinn, P.O., Marisetty, A.L., Liu, B., Kamal, M.M., Singh, S.K., Bady, P., Lu, L., Wani, K.M., Veo, B.L., Gumin, J., Kassem, D.H., Robinson, F., Weng, C., Baladandayuthapani, V., Suki, D., Colman, H., Bhat, K.P., Sulman, E.P., Aldape, K., Colen, R.R., Verhaak, R.G., Lu, Z., Fuller, G.N., Huang, S., Lang, F.F., Sawaya, R., Hegi, M., Majumder, S. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci., 35(45): 15097-112,2015.

12.   Balasubramaniyan, V., Vaillant, B., Wang, S., Gumin, J., Butalid, M.E., Sai, K., Mukheef, F., Kim, S.H., Boddeke, H.W., Lang, F., Aldape, K., Sulman, E.P., Bhat, K.P*., and Colman, H*. Aberrant mesenchymal differentiation of glioma stem-like cells: Implication for therapeutic targeting. Oncotarget., 6(31): 31007-17, 2015

13.   Kim, S-H., Joshi, K., Ezhilarasan, R., Myers, T.R., Siu, J., Gu, J., Nakano-Okuno, M., Taylor, D., Minata, M., Sulman, E.P., Lee, J., Bhat, K.P., Salcini, A.E., and Nakano, I.EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner. Stem Cell Rep., 4(2): 226-38, 2015.

2014

14.   Conroy, S., Kruyt, F.A., Joseph, J.V., Balasubramaniyan, V., Bhat, K.P., Wagemakers, M., Enting, R.H., Walenkamp, A.M., and Dunnen, W.F. Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach. PLoS One, 9(12): 2014.

15.   Joseph, J.V., Conroy, S., Tomar, T., Eggens-Meijer, E., Bhat, K., Copray, S., Walenkamp, A.M., Boddeke, E., Balasubramanyian, V., Wagemakers, M., den Dunnen, W.F., and Kruyt, F.A. TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis., 2 (5): e1443, 2014.

2013 and prior

16.   Bhat, K.P*., Balasubramaniyan, V., Vaillant, V., Ezhilarasan, R., Hollingsworth, F., James, J.D., Goodman, L.D., Conroy, S., Wani, S., Wang, S., Gumin, J., Raj, D., Raghunathan, A., Joshi, K., Pelloski, C.E., Heimberger, A., Lang, F.F., denDunnen, W.F.A., Boddeke, H.W.D.G.M.,  Phillips, H.S., Nakano, I., Colman, H., Sulman, E.P*., and Aldape, K*. Mesenchymal differentiation induced by NFkB promotes radiation resistance in glioblastoma. Cancer Cell**, 24 (3): 331-46, 2013. *corresponding authors.

**Editor’s Choice: Cutting EMT at the Pass, Sci. Signal., 293 (6), 223, 2013.

17.   Doucette, T.A., Kong, L.Y., Yang, Y., Ferguson, S.D., Yang, J., Wei, J., Qiao, W., Fuller, G.N., Bhat, K.P., Aldape, K., Priebe, W., Bögler, O., Heimberger, A.B., and Rao, G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol., 14(9):1136-45, 2012.

18.   Bhat, K.P*., Salazar, K.L., Balasubramaniyan, V., Wani, K., Heathcock, L., Hollingsworth, F., Gumin, J., Diefes, K.L., Kim, S.H., Turski, A., Azodi, Y., Yang, Y., Doucette, T., Colman, H., Sulman, E.P., Lang, F.F., Rao, G., Copray, S., Vaillant, B.D., Aldape, K.D*. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev**., 25(24):2594-609, 2011. *corresponding authors.

**Breaking Advances in Cancer Research. Proneural-to-mesenchymal transitions in brain tumors. Cancer Res., 72:377-378, 2012.

**Cancer stem cells: TAZ takes centre stage. Nat. Rev. Cancer, 12 (2): 82, 2012.

**Faculty of 1000 prime.

19.   Singh, M.M., Manton, C.A., Bhat, K.P., Tsai, W.W., Aldape, K., Barton, M.C., Chandra, J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol., 13(8):894-903, 2011.

20.   Gu, D., Tonthat, N.K., Lee, M., Ji, H., Bhat, K.P., Hollingsworth, F., Aldape, K.D., Schumacher, M.A., Zwaka, T.P., McCrea, P.D. Caspase-3 cleavage links delta-catenin to the novel nuclear protein ZIFCAT. J Biol Chem., 286(26):23178-88, 2011.

21.   Colman, H., Zhang, L., Sulman, E.P., McDonald, J.M., Shooshtari, N.L., Rivera, A., Popoff, S., Nutt, C.L., Louis, D.N., Cairncross, J.G., Gilbert, M.R., Phillips, H.S., Mehta, M.P., Chakravarti, A., Pelloski, C.E., Bhat, K., Feuerstein, B.G., Jenkins, R.B., Aldape, K. A multigene predictor of outcome in glioblastoma. Neuro Oncol., 12(1):49-57, 2010.

22.   Macias, E., Jin, A., Deisenroth, C., Bhat, K.P., Mao, H., Lindström, M.S., Zhang, Y. Mdm2 zinc finger is essential for ribosomal protein mediated stabilization of p53 and suppression of Myc-induced lymphomagenesis. Cancer Cell, 18(3):231-43, 2010.

23.   Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., Verhaak, R.G., Hoadley, K.A., Hayes, D.N., Perou, C.M., Schmidt, H.K., Ding, L., Wilson, R.K., Van Den Berg, D., Shen, H., Bengtsson, H., Neuvial, P., Cope, L.M., Buckley, J., Herman, J.G., Baylin, S.B., Laird, P.W., Aldape, K; The Cancer Genome Atlas Research Network.  Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell, 17(5):510-22, 2010.

24.   Martin, V., Xu, J., Pabbisetty, S.K., Alonso, M.M., Liu, D., Lee, O.H., Gumin, J., Bhat, K.P., Colman, H., Lang, F.F., Fueyo, J., Gomez-Manzano, C. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene, 28(24):2358-63, 2009.

25.   Bhat, K.P.,^* Pelloski, C.P., Wang, Y., Kim, S.H., Delacruz, C., Rehli, M and Aldape, K.D. Selective repression of YKL-40 by NFkB in glioma involves recruitment of histone deacetylase-1 and -2. FEBS Lett., 582(21-22):3193-200, 2008. ^*corresponding author.

26.   Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H.V., Lindstrom, M.S., Bhat, K.P., Godfrey, V.L., Evan, G.I., Zhang, Y. Targeted Inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell, 12(4):355-66, 2007.

27.   Pelloski C.E., Ballman K.V., Furth A.F., Zhang L., Lin E., Bhat K.P., McDonald J.M., Yung W.K.A., Colman H., Woo S.Y., Heimberger A.B., Suki D., Prados M., Chang S., Barker S.G., Buckner J.C., James C.D., and Aldape K.D. EGFRvIII status defines distinct subtypes of glioblastoma. J. Clin. Onc., 25(16):2288-94, 2007.